The travel vaccines market in Europe is expected to grow from US$ 995.47 million in 2021 to US$ 1,885.56 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028.
Hepatitis, HIV/AIDS, human papillomavirus (HPV), meningococcal disease, typhoid, and yellow fever are among the various chronic diseases detected across the region. Similarly, in 2021, the Centers for Disease Control and Prevention (CDC) launched the global immunization strategic framework 2021-2030. The framework provides a plan to vaccinate against vaccine-preventable diseases (VPDs), such as hepatitis A and B. Moreover, there are different vaccine routines for travelers proposed by WHO to prevent the spread of deadly infectious diseases. The vaccine routine includes routine vaccines for review before traveling, vaccines for certain destinations, and vaccines demanded by certain countries. In most cases, booster doses of routine vaccines are required if people have not followed the regular schedule. Such initiatives by WHO and CDC enhance the vaccine demand, thereby driving its market growth. On the other hand, the COVID-19 outbreak threatened public health. Various emergency actions were initiated during the pandemic, of which the COVAX initiative was aggressively enacted. Vaccination against COVID-19 was mandatory for people worldwide. Governments in every region mandated vaccines for people traveling within and outside countries. The COVID-19 pandemic contributed significantly to travel vaccines. Thus, the factors mentioned above are driving the market growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe travel vaccines market . The Europe travel vaccines market is expected to grow at a good CAGR during the forecast period.
Abbott; Dynavax Technologies; Emergent BioSolutions Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; and Valneva SE are among the leading companies in the travel vaccines market in the region.
Hepatitis, HIV/AIDS, human papillomavirus (HPV), meningococcal disease, typhoid, and yellow fever are among the various chronic diseases detected across the region. Similarly, in 2021, the Centers for Disease Control and Prevention (CDC) launched the global immunization strategic framework 2021-2030. The framework provides a plan to vaccinate against vaccine-preventable diseases (VPDs), such as hepatitis A and B. Moreover, there are different vaccine routines for travelers proposed by WHO to prevent the spread of deadly infectious diseases. The vaccine routine includes routine vaccines for review before traveling, vaccines for certain destinations, and vaccines demanded by certain countries. In most cases, booster doses of routine vaccines are required if people have not followed the regular schedule. Such initiatives by WHO and CDC enhance the vaccine demand, thereby driving its market growth. On the other hand, the COVID-19 outbreak threatened public health. Various emergency actions were initiated during the pandemic, of which the COVAX initiative was aggressively enacted. Vaccination against COVID-19 was mandatory for people worldwide. Governments in every region mandated vaccines for people traveling within and outside countries. The COVID-19 pandemic contributed significantly to travel vaccines. Thus, the factors mentioned above are driving the market growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe travel vaccines market . The Europe travel vaccines market is expected to grow at a good CAGR during the forecast period.
Europe Travel Vaccines Market Segmentation
Europe travel vaccines market is segmented into product, application, and country. The Europe travel vaccines market, by product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, the others segment held the largest share of the market. The Europe travel vaccines market, by application, is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the Europe travel vaccines market is segmented into France, Germany, Italy, the UK, Russia, and the Rest of Europe.Abbott; Dynavax Technologies; Emergent BioSolutions Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; and Valneva SE are among the leading companies in the travel vaccines market in the region.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Travel Vaccines Market- Market Landscape
5. Europe Travel Vaccines Market - Key Market Dynamics
6. Travel Vaccines Market - Europe Analysis
7. Europe Travel Vaccines Market Analysis - By Product
8. Europe Travel Vaccines Market Analysis - By Application
9. Europe Travel Vaccines Market - Country Analysis
10. Travel Vaccines Market-Industry Landscape
11. Company Profiles
12. Appendix
List of Figures
List of Tables
Companies Mentioned
- Abbott
- Dynavax Technologies
- Emergent BioSolutions Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Valneva SE.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 132 |
| Published | July 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 995.47 Million |
| Forecasted Market Value ( USD | $ 1885.56 Million |
| Compound Annual Growth Rate | 9.6% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 9 |
